McLernon David J, Dillon John, Donnan Peter T
Tayside Centre for General Practice, Health Informatics Centre, University of Aberdeen, Scotland, UK.
Med Decis Making. 2008 Jul-Aug;28(4):582-92. doi: 10.1177/0272989X08315240. Epub 2008 Apr 18.
Health-state utilities are essential for cost-utility analysis. Few estimates exist for liver disease in the literature. The authors' aim was to conduct a systematic review of health-state utilities in liver disease, to look at the variation of study designs used, and to pool utilities for some liver disease states.
A search of MED-LINE, EMBASE, and CINAHL from 1966 to September 2006 was conducted including key words related to liver disease and utility measuring tools. Articles were included if health-state utility tools or expert opinion were used. Variance-weighted mean utility estimates were pooled using metaregression adjusting for disease state and utility assessment method.
Thirty studies measured utilities of liver diseases/disease states. Half of these estimated utilities for hepatitis viruses: hepatitis A (n = 1), hepatitis B (n = 4), and hepatitis C (n = 10). Others included liver transplant (n= 6) and chronic liver disease (n= 5) populations. Twelve utility methods were used throughout. The EQ-5D (n = 10) was most popular method, followed by visual analogue scale (n = 9), time tradeoff (n = 6), and standard gamble (n = 4). Respondents were patients (n= 16), an expert panel (n = 10), non-liver diseases adults ( n=2), patient and expert (n = 1), and patient and healthy adult (n = 1). Type of perspective included community (n=21), patient (n=4), and both (n = 5). The pooled mean estimates in hepatitis C with moderate disease, compensated cirrhosis, decompensated cirrhosis, and post-liver transplant using the EQ-5D were 0.75, 0.75, 0.67, and 0.71, respectively. The change in these utilities using different methods were -0.07 (visual analogue scale), -0.01 (health utilities index version 3), +0.04 (standard gamble), + 0.08 (health utilities index version 2), + 0.12 (time tradeoff), and + 0.15 (standard gamble-transformed visual analogue scale).
The authors have created a valuable liver disease- based utility resource from which researchers and policy makers can easily view all available utility estimates from the literature. They have also estimated health-state utilities for major states of hepatitis C.
健康状态效用值对于成本效用分析至关重要。文献中关于肝脏疾病的效用值估计很少。作者的目的是对肝脏疾病的健康状态效用值进行系统评价,研究所使用的研究设计的差异,并汇总某些肝脏疾病状态的效用值。
检索了1966年至2006年9月的MEDLINE、EMBASE和CINAHL数据库,包括与肝脏疾病和效用测量工具相关的关键词。如果使用了健康状态效用工具或专家意见,则纳入相关文章。使用元回归对疾病状态和效用评估方法进行调整,汇总方差加权平均效用估计值。
30项研究测量了肝脏疾病/疾病状态的效用值。其中一半估计了肝炎病毒的效用值:甲型肝炎(n = 1)、乙型肝炎(n = 4)和丙型肝炎(n = 10)。其他包括肝移植人群(n = 6)和慢性肝病人群(n = 5)。总共使用了12种效用评估方法。欧洲五维度健康量表(EQ - 5D,n = 10)是最常用的方法,其次是视觉模拟量表(n = 9)、时间权衡法(n = 6)和标准博弈法(n = 4)。受访者包括患者(n = 16)、专家小组(n = 10)、非肝脏疾病成年人(n = 2)、患者和专家(n = 1)以及患者和健康成年人(n = 1)。视角类型包括社区(n = 21)、患者(n = 4)以及两者兼顾(n = 5)。使用EQ - 5D对中度丙型肝炎、代偿期肝硬化、失代偿期肝硬化和肝移植后的汇总平均效用估计值分别为0.75、0.75、0.67和0.71。使用不同方法时这些效用值的变化分别为:视觉模拟量表 - 0.07、健康效用指数第3版 - 0.01、标准博弈法 + 0.04、健康效用指数第2版 + 0.08、时间权衡法 + 0.12以及标准博弈法转换的视觉模拟量表 + 0.15。
作者创建了一个有价值的基于肝脏疾病的效用资源,研究人员和政策制定者可以从中轻松查看文献中所有可用的效用估计值。他们还估计了丙型肝炎主要状态的健康状态效用值。